GLP Research Compounds Compared: Single, Dual and Triple Agonists

Incretin-pathway research compounds differ mainly in how many receptors they activate. GLP-1(S) targets the GLP-1 receptor alone. GLP-2(T) adds the GIP receptor, mazdutide pairs GLP-1 with the glucagon receptor, and GLP-3(R) activates all three. Amylin-pathway compounds such as eloralintide and cagrilintide act on a separate receptor family. This guide compares their receptor targets and structure data.

The receptors involved

• GLP-1 receptor (GLP-1R): responds to glucagon-like peptide-1, a gut hormone that signals after nutrient intake. It is the most widely studied incretin receptor.
• GIP receptor (GIPR): responds to glucose-dependent insulinotropic polypeptide, the second incretin hormone.
• Glucagon receptor (GCGR): responds to glucagon and is studied for its role in energy expenditure and hepatic lipid metabolism.
• Amylin receptors: calcitonin receptor complexes that respond to amylin, a hormone co-secreted with insulin. This pathway is distinct from incretin signaling.

Compounds compared

Single agonist: GLP-1(S)

GLP-1(S) is a GLP-1 receptor agonist with a fatty-acid side chain that binds albumin, which extends its half-life compared with native GLP-1. Because it acts on one receptor, it is used as a reference point for isolating GLP-1R signaling in preclinical models.

Dual agonists: GLP-2(T) and mazdutide

Dual agonists are single peptides engineered to activate two receptors. GLP-2(T) combines GIP and GLP-1 receptor activity, which researchers use to study how the two incretin pathways interact. Mazdutide, an oxyntomodulin analog, combines GLP-1 and glucagon receptor activity, adding the glucagon pathway’s effects on energy expenditure and lipid metabolism.

Triple agonist: GLP-3(R)

GLP-3(R) activates the GIP, GLP-1 and glucagon receptors from a single molecule. Triple agonists let researchers study the combined effect of all three pathways without combining separate compounds, and compare that combined signal against single and dual agonists.

The amylin pathway: eloralintide and cagrilintide

Amylin agonists work through calcitonin-family receptors rather than incretin receptors. Eloralintide is a selective amylin receptor agonist. Cagrilintide is a long-acting amylin analog that also acts on the calcitonin receptor. Because the amylin and incretin pathways are separate, combining them is an active area of preclinical metabolic research.

Storage

All of these are supplied as lyophilized peptides. Store sealed vials at −20 °C long-term or 2–8 °C short-term, away from light. See How to Store Lyophilized Peptides for full handling guidance.

FAQ

What does “single, dual or triple agonist” mean?
It is the number of receptors one molecule activates. A single agonist targets one receptor; a dual or triple agonist is one peptide designed to activate two or three.

Is a Certificate of Analysis available?
Yes. Each product page has a “View Certificate of Analysis” button for the current lot’s third-party COA.

Do you provide use or dosing guidance?
No. These compounds are sold strictly for laboratory research, and orders indicating human or animal use are cancelled.

References

1. Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2013;17(6):819–837.
2. Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27(4):740–756.
3. Müller TD, Finan B, Clemmensen C, DiMarchi RD, Tschöp MH. The new biology and pharmacology of glucagon. Physiol Rev. 2017;97(2):721–766.
4. Hay DL, Chen S, Lutz TA, Parkes DG, Roth JD. Amylin: pharmacology, physiology, and clinical potential. Pharmacol Rev. 2015;67(3):564–600.
5. Kruse T, et al. Development of cagrilintide, a long-acting amylin analogue. J Med Chem. 2021;64(15):11183–11194.

All Next Level Compounds products are for laboratory research use only. Not for human consumption.